AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 23095007 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 50
Study 19919291 — intervention group
Group type: EXPERIMENTAL
Intervention: Interpersonal counselling (IPC)
Number of subjects: 103
Study 19919291 — intervention group
Group type: COMPARATOR
Intervention: Normal care (Control)
Number of subjects: 103
Study 17440526 — intervention group
Group type: EXPERIMENTAL
Intervention: Glutamine-supplemented HPN (10 g of glutamine)
Number of subjects: 35
Study 17440526 — intervention group
Group type: COMPARATOR
Intervention: Standard HPN
Number of subjects: 35
Study 17440526 — intervention group
Group type: EXPERIMENTAL
Intervention: Glutamine-supplemented HPN
Number of subjects: 35
Study 16620196 — intervention group
Group type: EXPERIMENTAL
Intervention: Transtheoretical Model (TTM) expert system intervention
Number of subjects: 404
Study 12785564 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality Improvement (QI) interventions
Number of subjects: 1269
Study 12785564 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 1269
Study 10722537 — intervention group
Group type: EXPERIMENTAL
Intervention: Transthoracic echocardiography using high frequency (7.5 MHz) transducers
Number of subjects: 60
Study 9372376 — intervention group
Group type: EXPERIMENTAL
Intervention: Allopurinol
Number of subjects: 24
Study 8436095 — intervention group
Group type: EXPERIMENTAL
Intervention: Fatty fish consumption
Number of subjects: 28
Study 8436095 — intervention group
Group type: COMPARATOR
Intervention: Red meat consumption
Number of subjects: 28
Study 4027101 — intervention group
Group type: EXPERIMENTAL
Intervention: Subarachnoid anaesthesia (SAB)
Number of subjects: 40
Study 4027101 — intervention group
Group type: COMPARATOR
Intervention: General anaesthesia (GA)
Number of subjects: 40
Study 31884740 — intervention group
Group type: EXPERIMENTAL
Intervention: Beraprost Sodium (BPS)
Number of subjects: 52
Study 31884740 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PCB)
Number of subjects: 52
Study 30400806 — intervention group
Group type: EXPERIMENTAL
Intervention: Written information on a breast milk substitute at discharge (Group A, n=405)
Number of subjects: 802
Study 30400806 — intervention group
Group type: COMPARATOR
Intervention: No written information on a breast milk substitute at discharge (Group B, n=397)
Number of subjects: 802
Study 30400806 — intervention group
Group type: COMPARATOR
Intervention: Group A vs Group B
Number of subjects: 802
Study 26509379 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 min of pulsing sinusoidal vibration
Number of subjects: 10
Study 26509379 — intervention group
Group type: COMPARATOR
Intervention: Control (no vibration)
Number of subjects: 10
Study 25285531 — intervention group
Group type: EXPERIMENTAL
Intervention: Obatoclax 20 mg/day (3 h × 3 d)
Number of subjects: 12
Study 25285531 — intervention group
Group type: COMPARATOR
Intervention: Obatoclax 60 mg/day (24 h × 3 d)
Number of subjects: 12
Study 22556172 — intervention group
Group type: EXPERIMENTAL
Intervention: Test formulation of omeprazole (OPZ), 40 mg single dose
Number of subjects: 32
Study 22556172 — intervention group
Group type: COMPARATOR
Intervention: Reference formulation of omeprazole (OPZ)
Number of subjects: 32
Study 20053692 — intervention group
Group type: EXPERIMENTAL
Intervention: tenofovir disoproxil fumarate + emtricitabine
Number of subjects: 91
Study 20053692 — intervention group
Group type: COMPARATOR
Intervention: Control (baseline antiretroviral regimen)
Number of subjects: 91
Study 18086590 — intervention group
Group type: EXPERIMENTAL
Intervention: PUVA plus up to 4 UVB 308-nm radiations
Number of subjects: 272
Study 18086590 — intervention group
Group type: COMPARATOR
Intervention: PUVA monotherapy
Number of subjects: 272
Study 15991879 — intervention group
Group type: EXPERIMENTAL
Intervention: Neodolpasse (fixed-dose combination of orphenadrine and diclofenac)
Number of subjects: 24
Study 15991879 — intervention group
Group type: EXPERIMENTAL
Intervention: Orphenadrine
Number of subjects: 24
Study 15991879 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofenac
Number of subjects: 24
Study 15991879 — intervention group
Group type: COMPARATOR
Intervention: Saline solution (placebo)
Number of subjects: 24
Study 12821547 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood cultures positive for Staphylococcus aureus
Number of subjects: 5500
Study 12821547 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood cultures positive for other pathogens
Number of subjects: 5500
Study 12821547 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood cultures with no growth
Number of subjects: 5500
Study 12821547 — intervention group
Group type: EXPERIMENTAL
Intervention: No blood cultures obtained
Number of subjects: 5500
Study 12821547 — intervention group
Group type: COMPARATOR
Intervention: Negative blood cultures
Number of subjects: 5500
Study 10842278 — intervention group
Group type: EXPERIMENTAL
Intervention: Concentric isokinetic leg extension training (6 sets, 3 days/week for 12 weeks at 90 degrees/s)
Number of subjects: 21
Study 10842278 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 21
Study 9016417 — intervention group
Group type: EXPERIMENTAL
Intervention: Warfarin prescribed
Number of subjects: 189
Study 9016417 — intervention group
Group type: EXPERIMENTAL
Intervention: Warfarin judged appropriate
Number of subjects: 189
Study 9016417 — intervention group
Group type: EXPERIMENTAL
Intervention: Warfarin prescribed to older patients
Number of subjects: 189
Study 9016417 — intervention group
Group type: EXPERIMENTAL
Intervention: Odds ratio for older patients
Number of subjects: 189
Study 1352024 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron 0.15 mg/kg + dexamethasone 20 mg
Number of subjects: 267
Study 1352024 — intervention group
Group type: COMPARATOR
Intervention: Metoclopramide 3 mg/kg + dexamethasone + diphenhydramine 50 mg
Number of subjects: 267
Study 1352024 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron + dexamethasone
Number of subjects: 267
Study 1352024 — intervention group
Group type: COMPARATOR
Intervention: Metoclopramide + dexamethasone + diphenhydramine
Number of subjects: 267
Study 3848264 — intervention group
Group type: EXPERIMENTAL
Intervention: Kallikrein 600 units daily for 3-6 months
Number of subjects: 75
Study 3848264 — intervention group
Group type: COMPARATOR
Intervention: Control group (30 infertile men)
Number of subjects: 75
Study 3848264 — intervention group
Group type: EXPERIMENTAL
Intervention: Kallikrein
Number of subjects: 75
Study 31051049 — intervention group
Group type: EXPERIMENTAL
Intervention: Medium lithium concentration mineral water (171 µg L‐1)
Number of subjects: 30
Study 31051049 — intervention group
Group type: EXPERIMENTAL
Intervention: High lithium concentration mineral water (1724 µg L‐1)
Number of subjects: 30
Study 31051049 — intervention group
Group type: COMPARATOR
Intervention: Low lithium concentration mineral water (1.7 µg L‐1)
Number of subjects: 30
Study 29217214 — intervention group
Group type: EXPERIMENTAL
Intervention: Good School Toolkit (intervention group)
Number of subjects: 42
Study 29217214 — intervention group
Group type: COMPARATOR
Intervention: Waitlisted control group (control group)
Number of subjects: 42
Study 26190359 — intervention group
Group type: EXPERIMENTAL
Intervention: OrCaSS protocol (intervention group - IG)
Number of subjects: 18
Study 26190359 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group - UCG)
Number of subjects: 18
Study 24693988 — intervention group
Group type: EXPERIMENTAL
Intervention: Eccentric isokinetic strengthening
Number of subjects: 80
Study 24693988 — intervention group
Group type: COMPARATOR
Intervention: Concentric isokinetic strengthening
Number of subjects: 80
Study 20837967 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes mellitus (DM) patients
Number of subjects: 89
Study 20837967 — intervention group
Group type: COMPARATOR
Intervention: Control subjects without DM
Number of subjects: 89
Study 16229689 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 degrees head-up position
Number of subjects: 35
Study 12018787 — intervention group
Group type: EXPERIMENTAL
Intervention: Attention to one of the two orientations of the elements of a monocular texture
Number of subjects: 0
Study 12018787 — intervention group
Group type: EXPERIMENTAL
Intervention: Texture briefly presented to the opposite eye
Number of subjects: 0
Study 12018787 — intervention group
Group type: EXPERIMENTAL
Intervention: Attention to specific features
Number of subjects: 0
Study 9630129 — intervention group
Group type: EXPERIMENTAL
Intervention: Family practice
Number of subjects: 509
Study 9630129 — intervention group
Group type: COMPARATOR
Intervention: Internal medicine
Number of subjects: 509
Study 7848544 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifampicin (rifampin)
Number of subjects: 0
Study 7848544 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinolones
Number of subjects: 0
Study 3075649 — intervention group
Group type: EXPERIMENTAL
Intervention: Active treatment (chiropractic adjustments of the thoracic spine T1-T5)
Number of subjects: 21
Study 3075649 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 21
Study 3075649 — intervention group
Group type: COMPARATOR
Intervention: No treatment control
Number of subjects: 21
Study 11799430 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary stenting
Number of subjects: 135
Study 11799430 — intervention group
Group type: COMPARATOR
Intervention: Balloon PTCA
Number of subjects: 135
Study 30617476 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulator-based training until passing a validated test scored by a blinded reviewer
Number of subjects: 20
Study 30617476 — intervention group
Group type: COMPARATOR
Intervention: No intervention prior to standard clinical ultrasound training on patients
Number of subjects: 20
Study 30509293 — intervention group
Group type: EXPERIMENTAL
Intervention: Sensor-augmented pump (SAP) with predictive low glucose suspend and alerts
Number of subjects: 36
Study 30509293 — intervention group
Group type: COMPARATOR
Intervention: Insulin pump with flash glucose measurement (FGM) device
Number of subjects: 36
Study 26433730 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fidelity simulation game with the same cases
Number of subjects: 61
Study 26433730 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fidelity text-based patient cases
Number of subjects: 61
Study 26433730 — intervention group
Group type: COMPARATOR
Intervention: Control group working on an e-module
Number of subjects: 61
Study 24851794 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative platelet-rich plasma (PRP)
Number of subjects: 40
Study 24851794 — intervention group
Group type: COMPARATOR
Intervention: Control (no PRP)
Number of subjects: 40
Study 22526685 — intervention group
Group type: EXPERIMENTAL
Intervention: Minocycline plus treatment as usual (TAU)
Number of subjects: 144
Study 22526685 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus treatment as usual (TAU)
Number of subjects: 144
Study 21134046 — intervention group
Group type: EXPERIMENTAL
Intervention: BoNTA (botulinum toxin type A free of complexing proteins)
Number of subjects: 21
Study 21134046 — intervention group
Group type: COMPARATOR
Intervention: BTXCo (botulinum toxin type A complex)
Number of subjects: 21
Study 17893629 — intervention group
Group type: EXPERIMENTAL
Intervention: 6% hydroxyethylstarch 130/0.4 (n = 25)
Number of subjects: 50
Study 17893629 — intervention group
Group type: COMPARATOR
Intervention: 5% human albumin (n = 25)
Number of subjects: 50
Study 15261920 — intervention group
Group type: EXPERIMENTAL
Intervention: Emergency coronary angiography with or without rescue PCI
Number of subjects: 307
Study 15261920 — intervention group
Group type: COMPARATOR
Intervention: Conservative treatment
Number of subjects: 307
Study 11791061 — intervention group
Group type: EXPERIMENTAL
Intervention: Stapled anastomosis
Number of subjects: 207
Study 11791061 — intervention group
Group type: COMPARATOR
Intervention: Handsewn anastomosis
Number of subjects: 207
Study 9842818 — intervention group
Group type: COMPARATOR
Intervention: Fentanyl 25 microg (F)
Number of subjects: 65
Study 9842818 — intervention group
Group type: COMPARATOR
Intervention: Bupivacaine 2.5 mg (B)
Number of subjects: 65
Study 9842818 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl 25 microg + Bupivacaine 2.5 mg (F + B)
Number of subjects: 65
Study 8077066 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose oral nicorandil (5, 10, 20, or 30 mg)
Number of subjects: 42
Study 8077066 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study 2684380 — intervention group
Group type: EXPERIMENTAL
Intervention: Buspirone (5 mg) administered BID, titrated to optimal dose
Number of subjects: 119
Study 2684380 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam (5 mg) administered BID, titrated to optimal dose
Number of subjects: 119
Study 2684380 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 119
Study 1189985 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycerol infusion
Number of subjects: 106
Study 1189985 — intervention group
Group type: COMPARATOR
Intervention: Control group (no glycerol infusion)
Number of subjects: 106
Study 31280641 — intervention group
Group type: EXPERIMENTAL
Intervention: Hysteroscopy
Number of subjects: 136
Study 31280641 — intervention group
Group type: COMPARATOR
Intervention: Laparoscopy
Number of subjects: 136
Study 29225332 — intervention group
Group type: EXPERIMENTAL
Intervention: Endotoxin (0.8 ng/kg lipopolysaccharide iv)
Number of subjects: 15
Study 25449994 — intervention group
Group type: EXPERIMENTAL
Intervention: Dolutegravir alone, fasting
Number of subjects: 24
Study 25449994 — intervention group
Group type: EXPERIMENTAL
Intervention: Dolutegravir with calcium carbonate, fasting
Number of subjects: 24
Study 25449994 — intervention group
Group type: EXPERIMENTAL
Intervention: Dolutegravir with ferrous fumarate, fasting
Number of subjects: 24
Study 25449994 — intervention group
Group type: EXPERIMENTAL
Intervention: Dolutegravir with calcium carbonate or ferrous fumarate with a moderate-fat meal
Number of subjects: 24
Study 25449994 — intervention group
Group type: EXPERIMENTAL
Intervention: Dolutegravir administered 2 hours before calcium carbonate or ferrous fumarate, fasting
Number of subjects: 24
Study 23377194 — intervention group
Group type: EXPERIMENTAL
Intervention: drospirenone-ethinyl estradiol (DEE)
Number of subjects: 42
Study 23377194 — intervention group
Group type: EXPERIMENTAL
Intervention: drospirenone-ethinyl estradiol + metformin (M)
Number of subjects: 42
Study 22018267 — intervention group
Group type: EXPERIMENTAL
Intervention: Motor Learning Walking Program (MLWP)
Number of subjects: 70
Study 22018267 — intervention group
Group type: COMPARATOR
Intervention: Body-weight-supported treadmill training (BWSTT)
Number of subjects: 70
Study 19222055 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-contact therapeutic touch intervention (experimental group)
Number of subjects: 90
Study 19222055 — intervention group
Group type: COMPARATOR
Intervention: Routine care (control group)
Number of subjects: 90
Study 19222055 — intervention group
Group type: COMPARATOR
Intervention: Sound of a metronome set at a steady slow pace (placebo group)
Number of subjects: 90
Study 16865075 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil (0.5 microg/kg/min)
Number of subjects: 40
Study 16865075 — intervention group
Group type: COMPARATOR
Intervention: Fentanyl (5 microg/kg bolus)
Number of subjects: 40
Study 16865075 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil
Number of subjects: 40
Study 15560936 — intervention group
Group type: EXPERIMENTAL
Intervention: Eating disorders group (15 young women)
Number of subjects: 15
Study 15560936 — intervention group
Group type: COMPARATOR
Intervention: Healthy control group (15 healthy women)
Number of subjects: 15
Study 15560936 — intervention group
Group type: EXPERIMENTAL
Intervention: Eating disorders group (subgroup analysis)
Number of subjects: 15
Study 11192275 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up of cardiovascular events and deaths reported by GPs every 2 years.
Number of subjects: 7735
Study 11192275 — intervention group
Group type: EXPERIMENTAL
Intervention: Questionnaires mailed to surviving subjects.
Number of subjects: 7735
Study 11192275 — intervention group
Group type: EXPERIMENTAL
Intervention: Mortality reporting from dual sources.
Number of subjects: 7735
Study 9308799 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhibin A
Number of subjects: 47
Study 9308799 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhibin B
Number of subjects: 47
Study 9308799 — intervention group
Group type: EXPERIMENTAL
Intervention: Activin A
Number of subjects: 47
Study 9308799 — intervention group
Group type: EXPERIMENTAL
Intervention: Follicular fluid androstenedione/oestradiol ratios
Number of subjects: 47
Study 8294627 — intervention group
Group type: EXPERIMENTAL
Intervention: NPSV (Non-invasive pressure support ventilation)
Number of subjects: 29
Study 8294627 — intervention group
Group type: EXPERIMENTAL
Intervention: NIPPV (Non-invasive intermittent positive pressure ventilation in assist-control mode)
Number of subjects: 29
Study 8294627 — intervention group
Group type: COMPARATOR
Intervention: NMV (Non-invasive mechanical ventilation)
Number of subjects: 29
Study 8294627 — intervention group
Group type: COMPARATOR
Intervention: Control (Standard medical therapy alone)
Number of subjects: 29
Study 3555040 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin 750 mg orally every 12 hours for a mean duration of 9.6 days (six to 18 days)
Number of subjects: 60
Study 3555040 — intervention group
Group type: COMPARATOR
Intervention: Cefotaxime 2.0 g intravenously every eight hours for a mean duration of 9.3 days (five to 14 days)
Number of subjects: 60
Study 31626906 — intervention group
Group type: EXPERIMENTAL
Intervention: Benralizumab 30 mg every 8 weeks
Number of subjects: 1493
Study 31626906 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1493
Study 30580277 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal anaesthesia with tourniquet
Number of subjects: 400
Study 30580277 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal anaesthesia without tourniquet
Number of subjects: 400
Study 30580277 — intervention group
Group type: EXPERIMENTAL
Intervention: General anaesthesia with tourniquet
Number of subjects: 400
Study 30580277 — intervention group
Group type: EXPERIMENTAL
Intervention: General anaesthesia without tourniquet
Number of subjects: 400
Study 27397921 — intervention group
Group type: COMPARATOR
Intervention: 1-minute heart rate recovery after peak exercise performance
Number of subjects: 47
Study 27397921 — intervention group
Group type: COMPARATOR
Intervention: Composite fitness score (including measures of strength, flexibility, and aerobic fitness)
Number of subjects: 47
Study 24453485 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA)
Number of subjects: 15
Study 24453485 — intervention group
Group type: COMPARATOR
Intervention: Minimal acupuncture (MA)
Number of subjects: 15
Study 22302665 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical corticosteroids applied with a squirt system
Number of subjects: 32
Study 22302665 — intervention group
Group type: COMPARATOR
Intervention: Topical corticosteroids applied with a nasal spray
Number of subjects: 32
Study 20675173 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical exercise
Number of subjects: 0
Study 20675173 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle interventions (including diet and physical exercise)
Number of subjects: 0
Study 20675173 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical training based on endurance and/or resistance exercises
Number of subjects: 0
Study 18756885 — intervention group
Group type: EXPERIMENTAL
Intervention: Off-pump coronary artery bypass graft (OPCAB)
Number of subjects: 60
Study 18756885 — intervention group
Group type: COMPARATOR
Intervention: On-pump coronary artery bypass graft (CABG)
Number of subjects: 60
Study 15742410 — intervention group
Group type: EXPERIMENTAL
Intervention: r-hepatitis B vaccine (BEVAC)
Number of subjects: 166
Study 15742410 — intervention group
Group type: COMPARATOR
Intervention: ENGERIX-B (commercial control)
Number of subjects: 166
Study 15742410 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 166
Study 12822626 — intervention group
Group type: EXPERIMENTAL
Intervention: Sole therapy TMR
Number of subjects: 81
Study 12822626 — intervention group
Group type: EXPERIMENTAL
Intervention: TMR with coronary artery bypass grafting
Number of subjects: 81
Study 12822626 — intervention group
Group type: COMPARATOR
Intervention: Coronary artery bypass grafting only (control group)
Number of subjects: 81
Study 10722237 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetic lesions (tumor necrosis factor-alpha expression)
Number of subjects: 20
Study 10722237 — intervention group
Group type: COMPARATOR
Intervention: Nondiabetic lesions (tumor necrosis factor-alpha expression)
Number of subjects: 20
Study 7720988 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-ASA (2 g)
Number of subjects: 50
Study 7720988 — intervention group
Group type: COMPARATOR
Intervention: 5-ASA (1 g)
Number of subjects: 50
Study 2041662 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone adjunctive treatment
Number of subjects: 160
Study 7209734 — intervention group
Group type: EXPERIMENTAL
Intervention: Radionuclide left ventricular ejection fraction (LVEF) during graded supine bicycle exercise
Number of subjects: 14
Study 30157532 — intervention group
Group type: EXPERIMENTAL
Intervention: Liraglutide (≤1.8 mg daily)
Number of subjects: 1260
Study 30157532 — intervention group
Group type: COMPARATOR
Intervention: Insulin
Number of subjects: 1260
Study 30157532 — intervention group
Group type: EXPERIMENTAL
Intervention: Liraglutide
Number of subjects: 1260
Study 30883686 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeting an arterial partial pressure of oxygen (PaO2) of 8 kPa
Number of subjects: 2928
Study 30883686 — intervention group
Group type: COMPARATOR
Intervention: Targeting an arterial partial pressure of oxygen (PaO2) of 12 kPa
Number of subjects: 2928
Study 26403465 — intervention group
Group type: EXPERIMENTAL
Intervention: Monthly dihydroartemisinin-piperaquine (DHA/PQ)
Number of subjects: 176
Study 26403465 — intervention group
Group type: COMPARATOR
Intervention: No chemoprevention
Number of subjects: 176
Study 26403465 — intervention group
Group type: EXPERIMENTAL
Intervention: Monthly dihydroartemisinin-piperaquine (DHA/PQ) with low PQ exposure
Number of subjects: 176
Study 26403465 — intervention group
Group type: EXPERIMENTAL
Intervention: Monthly dihydroartemisinin-piperaquine (DHA/PQ) with medium PQ exposure
Number of subjects: 176
Study 26403465 — intervention group
Group type: EXPERIMENTAL
Intervention: Monthly dihydroartemisinin-piperaquine (DHA/PQ) with high PQ exposure
Number of subjects: 176